Abstract 1660P
Background
Pancreatic cancer (PC) is among the deadliest malignancies with a 5-year survival rate of nearly 12%. Malignant proliferating cancer cells usually exhibit metabolism reprogramming, which is distinct from their normal counterparts, resulting in therapeutic vulnerabilities. However, the underlying mechanisms of aberrant cholesterol metabolism regulating PC progression are poorly understood. In the present study, we aimed to identify and investigate the role of a key cholesterol metabolic enzyme squalene epoxidase (SQLE) in tumorigenesis of PC.
Methods
Integrating analysis of The Cancer Genome Atlas (TCGA) cohort and multiple Gene Expression Omnibus (GEO) datasets was used to find the top up-regulated cholesterol homeostasis-related gene in PC. The IHC staining of tissue microarray composed of human PC samples were used to identify the clinical significance of SQLE in PC patients. The biological functions of SQLE and the potential therapeutic efficiency of SQLE inhibitors were assessed both in vitro and in vivo. Transcriptome analysis, untargeted metabolomics analysis, and related lipid detection were further performed to clarify the molecular mechanism of SQLE on PC development.
Results
We found SQLE expression was highly expressed in PC tissues compared with normal pancreatic tissues, and the upregulated SQLE predicted poor outcomes in PC patients. Additionally, we demonstrated that SQLE promoted the growth of PC both in vitro and in vivo. Mechanistically, inhibition of SQLE caused squalene accumulation-induced endoplasmic reticulum (ER) stress occurrence and subsequent cell apoptosis. Moreover, SQLE increased cholesterol de novo biosynthesis and maintained the stability of lipid rafts, which in turn activated Src/PI3K/Akt signalling. Finally, we found that pharmacological blockade of SQLE with terbinafine or NB-598 profoundly suppressed PC cell proliferation and xenograft tumor growth.
Conclusions
Our findings demonstrated the oncogenic role and tumor promoting mechanism of SQLE in PC. SQLE promotes PC growth by attenuating ER stress and promoting lipid rafts-regulated Src/PI3K/Akt signaling pathway, suggesting SQLE as a potential therapeutic target for PC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-002), the National High Level Hospital Clinical Research Funding (2022-PUMCH-D-001), the National Natural Science Foundation of China (82102810) and the fellowship of China Postdoctoral Science Foundation (2021M700501; 2022T150067).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22